Even Low Doses of HMOs Have a Positive Impact on Adults and Children, Study Finds

Article Outline

• Introduction
• Background on HMOs
• What are the effects of low doses of HMOs on the gut microbiome?
  • How did the researchers conduct their study?
• What were the results?
  • Summary of the main findings
  • Age-dependent differences in gut microbiome composition
  • From low doses onwards HMOs impact key fermentation parameters
  • HMOs increased bacterial cell density and maintained high diversity
  • Low doses of HMOs exert strong  Bifidobacteriaceae  effects
  • HMOs influence a range of health-associated metabolites even at low doses
• Summary

 Introduction

Human milk oligosaccharides (HMOs) have been the subject of many scientific research studies in recent years. Until now. Researchers from Switzerland and Belgium examined how dose impacts the gut microbiomes of 6-year-old children and adults, and the results are promising.

Background on HMOs

The gut microbiome plays an integral role in human health, supporting many of the body’s systems including the digestive, immune, and nervous systems. However, just like you and I, this unique ecosystem needs sustenance to survive and thrive. Much of the human diet provides the nutrients needed to feed the trillions of inhabitants in the gut, including fruit, vegetables, whole grains, and legumes which function as prebiotics.

Prebiotics are fibers that promote the growth and activity of gut microbes. One emerging prebiotic is human milk oligosaccharides. HMOs are the third most abundant component of human breast milk. They have many health benefits for both the developing and developed gut, including:

• promoting microbial diversity
• preventing pathogen adhesion
• protecting against viruses
• immune system development and strengthening[i]

What are the effects of dosage of HMOs on the gut microbiome?

Elison et al., (2016) investigated the effects of 2’-fucosyllactose (2’FL) and or Lacto-N-neotetraose (LNnT) over 2 weeks in healthy adults. Their research found that daily doses of up to 20 g a day were well-tolerated and increased the abundance and activity of Bifidobacteria.

Palsson and colleagues (2020) found that a daily 5 g supplement of 2’-FL and LNnT could normalize bowel habits in IBS patients, improving symptoms and quality of life[ii]. While Iribarren et al (2020) also found a 2’-FL and LNnT mix for 4 weeks increased the abundance of Bifidobacteria without worsening IBS symptoms[iii].

However, Bajic et al., (2024) thought that lower doses at 0.3 g/day, could be effective for modulating the gut microbiomes of both adults and children[iv]. The study was conducted after the same team had assessed the impact of a mix of 4 HMOs at a dose of 0.3-5 g/day compared to more traditional prebiotics, inulin, and fructooligosaccharides (FOS). HMOs were shown to be promising modulators of both adult and child microbiomes. The 4 HMOs used in the previous study were:

1. 2’-Fucosyllactose (2’-FL)
2. Lacto-N-neotetraose (LNnT)
3. 3’Sialyllactose
4. 6’Sialyllactose

Interestingly, the study highlighted some age-dependent differences, such as an increase in melatonin in children by 2’FL and LNnT and an increase in folic acid in adults by 3’SL.

The current study aimed to assess the impact of these 4 HMOs at doses of 0.3 to 5 g/day on the composition of the microbiome and metabolite production in adults and children.

How did the researchers conduct their study?

The researchers analyzed the same four HMOs as they did in their previous study (2’FL, LNnT, 3’SL, and 6’SL) at human equivalent doses of between 0.3 and 5g/day. SIFR® technology combined with an up-to-date multi-omics approach was used to evaluate the effects of the doses.

Figure 1.The researchers collected fresh fecal samples from 6 donors per age group. The selection criteria for adults included no antibiotic use in the previous 3 months, no probiotic use, no gastrointestinal disorders, no smoking, alcohol consumption that did not exceed 3 units per day, and a body mass index between 20 and 25. SIFR® technology assessed the impact of the four single HMOs at low doses on the gut microbiota of 6-year-old children and adults compared to a no-substrate control.

What were the results?

The study showed that overall the HMOs increased the production of short-chain fatty acids (SCFAs) in both adults and children and that the strength of the effects increased with the increasing doses. Here, we’ll take a closer look at some of the findings.

Summary of the main findings

• All HMOs significantly increased the production of SCFAs between doses of 0.3 and 5 g/day
• All doses of every HMO increased acetate and propionate in adults and children
• Each dose of each HMO, except the lowest doses of the two sialylated HMOs, increased butyrate production in adults
• LNnT specifically increased butyrate
• 6’SL had a significant impact on the production of propionate in adults
• All HMOs increased  Bifidobacteriaceae  in children
• 2’FL and LNnT increased Bifidobacteriaceae  in adults
• Increased in  Bifidobacteria  increased acetate production
• The beneficial effects of HMO administration goes beyond just SCFA; they also increase the production of other health-related metabolites

Age-dependent differences in gut microbiome composition

One of the first observations from the study was the difference in the composition of the fecal microbiota between adults and children. One of the key differentiators is the  Bifidobacteriaceae  family. The researchers noted that:

• The children’s microbiota was enriched with   catenulatum  and  B. pseudocatenulatum
• adolescentiswas the abundant bacteria in the adult microbiome

The observations mirror previous in vivo studies. For example, Derrien et al (2022) stated that the abundance of  Bifidobacterium  in the healthy adult microbiome is more than 90% with  B. longum and  B. adolescentis  being the most abundant species[v].

Figure 2.The abundance of  Bifidobacteria  species in the human adult microbiome.  B. longum  and  B. adolescentis  are the most abundant species.

Find out more about the effect of aging on the composition and diversity of the human gut microbiome here.

From low doses onwards HMOs impact key fermentation parameters

Across both adult and child microbiomes, all four HMOs impacted on key fermentation parameters at 24 hours in a dose-dependent manner. The following summarises the key findings:

• all 4 HMOs increased acetate, propionate and total SCFAs in adults and children
• all 4 HMOs significantly lowered the pH in adults and children
• 6’SL increased propionate production in adults given 5g/day
• All HMOs, particularly LNnT significantly increased butyrate production in adults except for 0.3 g/day of 3’SL and 0.5 – 1 g/day of 6’SL

Figure 3.In children, acetate and propionate increased from the lowest doses onwards with all 4 HMOs. In adults, butyrate production increased significantly with all HMOs except for the low doses of 3’SL and 6’SL. The results can be seen in the graph above; acetate (A&B), propionate (C&D), and butyrate (E&F).

An increased production of SCFAs is linked to better health outcomes. For example, an increase in butyrate was seen in both adults and children. Butyrate is the main energy source for colonocytes, the cells that line the gut, and has many important functions, particularly in gastrointestinal health. Therefore, identifying the HMOs that increase specific SCFA levels can be beneficial for future health applications[vi].

HMOs increased bacterial cell density and maintained high diversity

Interestingly, the no-substrate control recorded an increase in bacterial cell density over the 24 hours. The diversity also remained high, which helped to confirm the effectiveness of the SIFR® technology.

Compared to the control, the highest dose of 5 g/day increased bacterial cell density with all HMOs. When considering the richness of species, diversity was similar for all HMOs and the control in adults, but there was a significant reduction in children at high doses of 2’FL and 3’SL. These results suggest that some species become very abundant.

Low doses of HMOs exert strong Bifidobacteriaceaeeffects

All four HMOs exerted bifidogenic effects in children with 2’FL and LNnT having the same effect in adults. The effects of 2’FL, LNnT, 3’SL, and 6’SL on   Bifidobacteriaceae  and  Bacteroidaceae  are shown in the table below:

The increase in  Bacteroidaceae  by the sialylated HMOs was suspected to increase the abundance of the succinate converter,  Phascolarctobacterium faecium,  which increased when 6’SL was administered to children.

However, this wasn’t the only evidence of cross-feeding in the study. Veillonellaceae,  a member of the Firmicutes phylum, also had an increased abundance, particularly at the higher HMO doses and in children. This is likely to be because  Veillonellaceae  consumed the lactate produced by  Bifidobacteriaceae.

Did you know?You can increase your intake of sialylated HMOs with the SuperHMO® Prebiotic Mix with 5 key HMOs, including the 4 used in this study and lacto-N-tetraose (LNT).

There were also dose-dependent and HMO-dependent increases in several other Firmicutes bacteria:

The results also confirmed there were distinct differences in the bacteria between adults and children involved in HMO fermentation.

HMOs influence a range of health-associated metabolites even at low doses

Alongside the marked increases in SCFA production facilitated by HMOs, Bajic et al., also observed an increase in health-related metabolites. As the doses of the HMOs increased up to 5g/day, the effects on these metabolites became more potent.

The aromatic lactic acids, indole-3-lactic acid, and 3-phenyllactic acid were modulated by:

• 2’FL and LNnT in adults
• 3’SL and 6’SL in children

The impact of the HMOs at low doses and beyond on health-related metabolites is shown in Figure 4.

Figure 4.Heat maps show how the 4 HMOs impact a range of metabolites at different doses.

The increase in these lactic acids is important because they have been linked to immune function. For example, indole-3-lactic acid contributes to immune cell differentiation and the synthesis of cytokines, small proteins that are important in cell signaling[vii]. It has also been identified as a signaling molecule for the gut-brain axis and is linked to a reduction in inflammation in the colon[viii].

Summary

Overall, the study by Bajic and colleagues (2024) found that HMOs have a positive impact on the abundance of healthy bacteria and the production of health-promoting microbial metabolites, even at doses below 5g/day. It’s likely the low doses are so impactful because of the keystone species that are prominent in the gut, namely those from the Bifidobacteriaceaefamily. These increased in abundance at a dose of just 0.5 g/day of LNnT in adults and 1 g/day in children with 2’FL. This study lays the foundation for future research looking at how specific HMOs and doses can be used to improve the health of adults and children via the specific modulation of the gut microbiota.

Written by: Leanne Edermaniger, M.Sc. Leanne is a professional science writer who specializes in human health and enjoys writing about all things related to the gut microbiome.  

Sources

[i] Wiciński M, Sawicka E, Gębalski J, Kubiak K, Malinowski B. Human Milk Oligosaccharides: Health Benefits, Potential Applications in Infant Formulas, and Pharmacology. Nutrients. 2020 Jan 20;12(1):266. doi: 10.3390/nu12010266. PMID: 31968617; PMCID: PMC7019891.

[ii] Palsson OS, Peery A, Seitzberg D, Amundsen ID, McConnell B, Simrén M. Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial. Clin Transl Gastroenterol. 2020 Dec;11(12):e00276. doi: 10.14309/ctg.0000000000000276. PMID: 33512807; PMCID: PMC7721220.

[iii] Iribarren C, Törnblom H, Aziz I, Magnusson MK, Sundin J, Vigsnaes LK, Amundsen ID, McConnell B, Seitzberg D, Öhman L, Simrén M. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2020 Oct;32(10):e13920. doi: 10.1111/nmo.13920. Epub 2020 Jun 14. PMID: 32536023.

[iv] Bajic D, Wiens F, Wintergerst E, Deyaert S, Baudot A, Abbeele PV. HMOs impact the gut microbiome of children and adults starting from low predicted daily doses. Metabolites. 2024 Apr 20;14(4):239. doi:10.3390/metabo14040239

[v] Derrien M, Turroni F, Ventura M, van Sinderen D. Insights into endogenous bifidobacterium species in the human gut microbiota during adulthood. Trends in Microbiology. 2022 Oct;30(10):940–7. doi:10.1016/j.tim.2022.04.004

[vi] Hodgkinson K, El Abbar F, Dobranowski P, Manoogian J, Butcher J, Figeys D, et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clinical Nutrition. 2023 Feb;42(2):61–75. doi:10.1016/j.clnu.2022.10.024

[vii] Larissa Jank M. Exploring the impact of indole-3-lactate in the gut-brain axis and multiple sclerosis: Larissa Jank, MD [Internet]. Neurology live; 2023 [cited 2024 Jul 30]. Available from: https://www.neurologylive.com/view/exploring-impact-indole-3-lactate-gut-brain-axis-multiple-sclerosis-larissa-jank

[viii] Ehrlich AM, Pacheco AR, Henrick BM, Taft D, Xu G, Huda MN, Mishchuk D, Goodson ML, Slupsky C, Barile D, Lebrilla CB, Stephensen CB, Mills DA, Raybould HE. Indole-3-lactic acid associated with Bifidobacterium-dominated microbiota significantly decreases inflammation in intestinal epithelial cells. BMC Microbiol. 2020 Nov 23;20(1):357. doi: 10.1186/s12866-020-02023-y. PMID: 33225894; PMCID: PMC7681996.